ASH Attendees Question Ethics, Results Of Major CLL Trials
Executive Summary
Trials of Roche’s Gazyva and Gilead’s idelalisib draw scrutiny as ASH attendees express concern about whether comparators were good enough. Investigator on Roche/AbbVie’s Bcl-2 inhibitor GDC-0199/ABT-199 study gets flak for lack of oversight that resulted in death.